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SUMMARY
Altered immune responses have been reported in head and neck cancer, and some of these responses have been associated with poor clinical 
outcomes. A multiple-array technology platform was used to simultaneously evaluate the levels of 25 cytokines. Pre-treatment serum levels 
were evaluated in 31 HNSCC patients and 6 healthy controls. The levels of 8 cytokines, specifically IL-1ra, IL-2, IL-5, IL-6, IL-8, IL-17, IFN-γ 
and IP-10, were significantly higher in patients than in controls. Among cancer patients we observed lower levels of IFN-γ and IL-7 in cases 
with nodal metastases compared to those with cN0 disease. We observed increases in the levels of some serum cytokines in HNSCC patients, as 
well as reductions in selected cytokines associated with regional progression. These findings provide an intriguing perspective on the develop-
ment and validation of novel markers for follow-up evaluations and predictions of regional spreading in HNSCC patients.
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RIASSUNTO 
È noto che nelle neoplasie della testa e del collo vi siano delle alterazioni della risposta immune, ed alcune di tali alterazioni sono state associate 
ad un peggioramento prognostico. Abbiamo utilizzato una piattaforma con una tecnologia multi-array per valutare simultaneamente i valori di 25 
citochine nel siero di 31 pazienti, affetti da carcinomi squamosi della testa e del collo prima del trattamento, e di 6 controlli sani. I livelli di 8 citochi-
ne, IL-1ra, IL-2, IL-5, IL-6, IL-8, IL-17, IFN-γ ed IP-10, sono risultati significativamente più elevati nei pazienti che nei controlli. Tra i pazienti i casi 
con metastasi linfonodali mostravano livelli significativamentre inferiori di IFN-γ ed IL-7 rispetto ai casi cN0. Pertanto alcune citochine tendono 
ad essere più elevate nei soggetti affetti da carcinomi squamocellulari della testa e del collo, ma nel contesto di tale gruppo di pazienti si osserva un 
calo specifico di alcune citochine in caso di metastasi linfonodali. Tali dati aprono prospettive interessanti soprattutto ai fini di una miglior defini-
zione del rischio di metastasi/recidive linfonodali con implicazioni sia in termini di impostazione terapeutica che di follow up.
PAROLE CHIAVE: Carcinomi squamosi della testa e collo • Metastasi linfonodali • Fattori predittivi • Citochine • Infiammazione  • Interferon-
gamma
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Introduction
Head and neck squamous cell carcinoma (HNSCC) rep-
resents approximately 3% of all malignant tumours in the 
United States 1 and Europe 2, but is much more prevalent 
in other parts of the world 3. The standard therapeutic ap-
proach, which includes surgery, irradiation and chemo-
therapy, either alone or in combination, has been some-
what modified over the last 30 years; however, the overall 
survival rate has not drastically improved 1 3.
The persistently high rate of advanced lesions is among 
the potential reasons for the failure to improve the HN-
SCC survival rate. In general, screening attempts have 
been completely unsuccessful, such that for the larynx, 
the most frequently affected primary site in European pa-
tients 4, where less than 1% of SCC patients are asympto-
matic at presentation. The definition of high-risk groups 
that should be submitted to screening would likely in-
crease this rate. Oncogenic viruses, particularly Epstein-
Barr and high-risk papillomavirus, have been shown to 
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play causative roles in subsets of nasopharyngeal  5 and 
oropharyngeal 6 cancers, respectively, and therefore might 
be a good starting point. Nevertheless, the most frequent 
site of origin for HNSCC are the oral cavity and larynx, 
for which the main proven risk factors remain cigarette 
smoking and alcohol consumption 3; however, these fac-
tors do not define a sufficiently restricted population to 
monitor for effective prevention and/or screening. 
Another issue in head and neck oncology is that the prog-
nostic stratification is inadequate because patients who 
are affected by tumours with similar clinicopathological 
parameters and are undergoing the same treatment can 
differ widely in their prognoses. This is likely due to the 
extreme biological heterogeneity of HNSCCs, and con-
tributes to the known controversies concerning therapeu-
tic algorithms (on management of cN0 necks) 7.
Many clinical and epidemiologic studies have suggested 
a strong association between inflammation, with its me-
diators, and cancer 8-11, including cancers of the head and 
neck 12-14.
In the present study, we investigated the serum concentra-
tions of various cytokines in patients with laryngeal and 
oral SCC, and compared these with the concentrations in 
healthy subjects, to identify alterations in inflammatory 
pathways associated with carcinogenesis. 
We tested a panel of 26 cytokines that are important in 
the inflammatory response and immune system regulation 
and associated with different immune pathways, giving 
specific information, and in particular concerning Th2 
and Th1 immune responses.
Cytokine levels were also correlated with tumour char-
acteristics (e.g., site of origin and T and N classification) 
and oncologic outcomes to identify parameters that might 
supplement TNM and other information currently avail-
able to clinicians to assess prognoses, treatment responses 
and clinical behaviours (e.g., tendency to regional metas-
tasis) of HNSCC patients.
Materials and methods
Patients 
From February 2010 to March 2012, we enrolled 31 pa-
tients (5 women, 26 men; age range, 32-82 years; mean, 
57 years) who were affected by primary, previously un-
treated and biopsy proven SCC arising from oral cavity 
or larynx, as evaluated by the multidisciplinary head and 
neck tumour board of the Policlinico Agostino Gemelli, 
Università Cattolica del Sacro Cuore, Rome, Italy.
Staging according to the TNM AJCC classification 
7th edition, and treatment recommendation were defined, 
patients signed informed consent for their participation in 
the present study, which had been previously approved by 
the ethical committee.
The circulating levels of interleukin-1b (IL-1b), interleu-
kin-1 receptor antagonist (IL-1Ra), IL-2, IL-4, IL-5, IL-6, 
IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-17, eotaxin, ba-
sic fibroblast growth factor (FGF-b), granulocyte colony-
stimulating factor (G-CSF), interferon-gamma (IFN-γ), 
IFN-γ-inducible protein 10 (IP-10), human monocyte 
chemoattractant protein 1 (HuMCP-1), macrophage in-
flammatory proteins-1-alpha and 1-beta (MIP-1α and 
1β), platelet-derived growth factor-BB (PDGF-BB), regu-
lated upon activation, normal T-cell expressed secreted 
(RANTES), tumour necrosis factor-alpha (TNF-α) and   
vascular endothelial growth factor (VEGF) were inves-
tigated in sera collected before primary treatment. All 
SCC originated from the oral cavity (n = 16) and larynx 
(n = 15), which are the most frequent sites of HNSCC 1. 
All patients had a history of cigarette smoking.
Selection of primary treatment modality was always 
shared in the institutional multidisciplinary head and neck 
tumour board. All oral cavity cases were treated primarily 
by surgery. As for laryngeal SCCs, in our tumour board 
treatment choice is based mainly on cT, and on the pa-
tient’s general condition and preference. Namely, we 
primarily irradiated cT1 and cT2 and we recommended 
primary surgery in cT4 cases; cT3 cases were discussed in 
the tumour board and underwent surgery or radiotherapy 
depending on the patient’s general conditions and feasi-
bility of function preservation surgery (supracricoid oper-
ations). Among patients who underwent primarily radio-
chemotherapy, there were also cT4 patients who refused 
the recommended total laryngectomy and preferred to try 
to keep their larynx, after having been informed about the 
lower survival rates reported in literature. Postoperative 
radiation (mostly associated with cisplatin) was adminis-
tered for pN2-3 disease, extracapsular spread and adverse 
pathologic primary site features including pT4 disease, 
perineural invasion, involvement of surgical margins, or 
lymphovascular invasion.
The follow-up time was calculated from the treatment 
date (surgery or final session of chemo/radiotherapy). 
For controls, sera were collected from 6 healthy sex and 
age-matched volunteers who were current smokers with 
personal histories negative for malignancy, without re-
cent trauma or surgery, and who were not pregnant. Per-
sonal data for cases and controls and clinical data for 
HNSCC patients are summarised in Table I. Peripheral 
venous blood was collected into Vacuette (Greiner bio-
one, Kremsmünster, Austria) tubes and was immediately 
centrifuged at 4°C and 4000 rpm for 5 minutes. Serum 
samples were collected and multiple aliquots were stored 
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at -80°C until analysis, at which time the serum concen-
trations of cytokines were determined in a multiplex cy-
tokine analysis.
Multiplex cytokine analysis
A Luminex xMAP system (Bio-Plex 200 System, Bio-
Rad Laboratories, Hercules, CA, USA), which is a mul-
tiplex biometric enzyme-linked immunosorbent assay 
(ELISA)-based immunoassay that contains dyed micro-
spheres conjugated to monoclonal antibodies specific 
for target proteins, was used according to the manufac-
turer’s instructions. The cytokines evaluated in the panel 
(BioPlex Human Cytokine Assay; BioRad) were IL-1β, 
IL1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, CXCL8 (IL-8), IL-9, 
IL-10, IL-12 (p70), IL-13, IL-17, basic FGF, eotaxin, G-
CSF , IFN-γ, IP-10, MCP-1, MIP-1a and β, PDGF-BB, 
RANTESTNF-α and VEGF.
The serum samples were diluted 1:4 and incubated with 
antibody-coupled beads. The resulting complexes were 
washed and incubated first with a biotinylated detection 
antibody and then with streptavidin-phycoerythrin prior 
to assessing the cytokine concentration titres. Concentrat-
ed human recombinant cytokines were provided by the 
vendor (BioRad, Inc.). Broad ranges of standards (1.95-
32,000 pg/ml) were used to establish standard curves with 
which to maximise the sensitivity and dynamic range of 
the assay. Cytokine levels were determined on a Bio-Plex 
array reader, an automated flow-based microfluidics de-
vice that uses a dual-laser fluorescent detector with re-
al-time digital signal processing for quantification. This 
instrument quantifies multiplex immunoassays in 96-well 
plates. The concentrations in pg/ml were calculated from 
standard curves with software provided by the manufac-
turer. A regression analysis was performed to derive an 
equation that was then used to predict the concentrations 
of cytokines in the serum samples.
Statistical analysis
Statistical analysis was performed with JMP software, re-
lease 7.0.1 (SAS Institute). The level was fixed at 0.05 
for all statistical tests. Correlations between nominal 
variables were evaluated with a c2 test. Differences in the 
concentrations of different cytokines between controls (c) 
and patients (p) and between the cN0 and cN+ cases were 
evaluated with a t-test. Differences among tumours that 
originated in the two sites (oral cavity vs. larynx), controls 
and among different the cT and cN classifications were 
evaluated by ANOVA variance analysis, and pairs were 
then compared with the Tukey-Kramer test. For a more 
thorough evaluation of the variations in serum cytokine 
levels along with increasing tumour staging, we trans-
formed the nominal cT and cN parameters to numerical 
variables (numeric T and N scores; cT4a = 4, cT4b = 5, 
cN2a = 2, cN2b = 3, cN2c = 4, cN3 = 5) and sought a 
linear fit by analysis of variance. The impact of different 
parameters on survival were evaluated by a Cox regres-
Table I. Characteristics of patients in the entire series according to the pri-
mary treatment group.
Characteristic Patients (n = 31) Controls (n = 6)
Age
Median 63
32-82
61
47-72Range
Sex-no. (%)
Male 26 (84%) 5 (83%)
Female 5 (16%) 1 (17%)
Smoking habits-no. (%)
Less than 10 pack/years 10 (32%) 2 (33%)
More than 10 pack/years 21 (68%) 4 (67%)
Drinking habits-no. (%)
Non drinker 12 (39%) 2 (33%)
1-4 glasses/day 13 (42%) 3 (50%)
More than 4 glasses a day 6 (19%) 1 (17%)
Follow up
Median 8.3
0.2-21
-
Range -
Site of primary-no. (%)
Oral cavity 16 (52%) -
Larynx 15 (48%) -
Primary treatment-no. (%)
Surgery 22 (71%) -
Radio+chemotherapy 9 (21%) -
TNM staging-no. (%)
I 3 (10%) -
II 9 (29%) -
III 2 (6%) -
IVa 17 (55%) -
T stage-no.(%)
T1 4 (13%) -
T2 12 (39%) -
T3 3 (9%) -
T4a 12 (39%) -
N stage-no.(%)
N0 17 (55%) -
N1 3 (10%) -
N2a 2 (6%) -
N2b 4 (13%) -
N2c 5 (16%) -
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sion analysis (only univariate because of the low numbers 
of cases and recorded events).
Results
Statistically significant differences between controls and 
patients with regard to concentrations of the different cy-
tokines are reported in Table II and schematically repre-
sented by box plots in Figure 1. The statistically signifi-
cant differences observed among the two different tumour 
sites and controls are shown in Figure 2. Two cytokines 
were significantly overexpressed only in patients with 
specific SCC subsites, namely IL-6 in laryngeal SCC pa-
tients and IP-10 in oral cavity SCC patients. 
We found no significant differences or correlations be-
tween the levels of various cytokines and the T classifica-
tion, although a trend (p = 0.0615 in the variance analysis) 
towards a positive correlation between the IP-10 levels 
and numeric T scores was observed.
However, when we evaluated the association between cy-
tokine levels and the N classification, a significant cor-
relation of lower levels of some with nodal involvement 
(IL-7, FGF-basic, IFN-γ , HuMIP-1a, see figure 3 on the 
right) and with the numeric N score were seen (IL-7, eo-
taxin, IFN-γ, see Figure 3 on the left).
In Cox univariate survival analysis, we observed that 
higher IFN-γ (p = 0.0218) and lower IL-1ra (p = 0.0376) 
levels were associated with longer disease-specific sur-
vival.
Discussion
We observed increases in the levels of several cytokines 
in sera from HNSCC patients compared to sera from 
controls. This observation confirms the well-known link 
between inflammation and cancer that has already been 
observed in head-and-neck oncology. This observation 
could be linked to the presence of the tumour and its in-
teractions with the host 8 15-18, or could indicate an immu-
nological predisposition to cancer development  8 11 15. In 
the former scenario, inflammatory mediators should be 
evaluated as tumour markers that could be employed in 
Table II. Mean values of cytokines in controls and cases (statistically significant differences are indicated with *).
Cytokine Value in controls (mean+SD) Value in cases (mean+SD)
IL-1b 3.3133333 ± 0.8841418 3.674 ± 0.8323154
IL-1ra* 174.90667 ± 17.770011 237.06833 ± 75.716824
IL-2* 1.715 ± 2.9156251 8.0387097 ± 7.2977836
IL-4 9.425 ± 2.0147332 11.432258 ± 2.3363158
IL-5* 3.4616667 ± 0.412864 4.4770968 ± 1.8866005
IL-6* 9.1083333 ± 1.1434232 14.095806 ± 4.3274864
IL-7 13.881667 ± 2.6957776 16.143548 ± 4.848343
IL-8* 32.186667 ± 5.5094489 40.000323 ± 10.059768
IL-9 33.548333 ± 18.8509 46.597097 ± 25.720585
IL-10 30.395 ± 33.645025 22.915161 ± 12.610672
IL-12 95.153333 ± 37.067161 132.97935 ± 84.327459
IL-13 12.19512,195 ± 3.6285024 14.570645 ± 5.7731684
IL-17* 190.29667 ± 61.275395 253.8671 ± 67.58494
Eotaxin 233.67167 ± 97.855583 243.08645 ± 112.18061
FGF-basic 47.305 ± 23.345764 55.560645 ± 27.172748
G-CSF 72.231667 ± 18.809514 75.645161 ± 16.2412
IFN-g* 311.015 ± 51.866943 376.45903 ± 75.010629
IP-10* 1488.3367 ± 510.41972 2502.8471 ± 1098.5081
Hu MCP-1(MCAF) 60.086667 ± 21.832594 45.274839 ± 16.429516
Hu MIP-1a 8.8483333 ± 2.2179217 9.0803226 ± 2.1559568
PDGF-bb 14614.73 ± 5313.271 17966.356 ± 4937.8699
MIP-1b 113.71333 ± 34.277828 118.45355 ± 30.917572
RANTES 9447.305 ± 850.45661 9032.6235 ± 1481.9593
TNF-alpha 39.131667 ± 7.2147 43.99129 ± 11.821503
VEGF 132.37667 ± 65.794253 203.30032 ± 175.79658
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Fig. 1. Box plots of 8 cytokines (for which the levels were significantly higher in sera from patients (p), compared to controls (c). P-values were obtained 
with a two-sided t-test.
99
Serum cytokines in head and neck squamous cell carcinoma
follow-up for early detection of recurrence; in the latter, 
certain immunological conditions might be risk factors 
for development of malignancy and could be taken into 
account when selecting subjects for screening.
Likely, both of these scenarios are true, and in our series, 
it was difficult to discriminate between the alterations that 
preceded and those that derived from cancer progression. 
In our patients, the cytokines with the most significant 
increases were IL-6 and IL-1Ra. Increased IL-6 levels 
have already been associated with HNSCC  19-21, as well 
as with IL-8  12 22, another upregulated cytokine among 
our patients. IL-6 might contribute to cancer progression 
through STAT-3-mediated paracrine or autocrine prolifer-
ative stimulation and through additional inhibitory effects 
on anti-tumour Th1 immune responses 23 24. Nevertheless, 
in contrast to previous studies, in the present series, we 
failed to demonstrate any correlation between IL-6 itself 
and the disease stage 25 or prognosis 19, although the lim-
ited number of patients and the short follow-up period 
might explain this result. Actually, in the present series, 
IL-6 was significantly increased only in laryngeal SCC 
patients, and the reasons for this observation remain to 
be clarified. We instead observed a correlation between 
increased levels of IL1-Ra and worse prognosis. IL1-Ra 
levels have been correlated with prognosis in Hodgkin 
lymphoma 26 and have been shown to be elevated in head 
and neck SCC tissues 27. IP-10 and its corresponding re-
ceptor CXCR3 have been shown to be involved in car-
cinogenesis  28 including malignant melanoma 29, ovarian 
carcinoma  30, multiple myeloma 31, B-cell lymphoma 32 
and basal cell carcinoma  33. In our series, the increased 
levels of IP-10 in patients with oral SCC, which are usu-
ally bulkier than laryngeal SCC, and in those with higher 
T scores (even if not significant), could suggest that IP-10 
levels are influenced by tumour volume. 
The prognostic role of IL-1Ra deserves in-depth evalua-
tion in larger perspective studies. Nevertheless, these re-
sults provide a perspective for the use of some cytokines 
as tumour markers in clinical practice, such as during fol-
low-up of HNSCC patients, also on account of the clear 
lack of reliable serum follow-up markers, of which the 
SCC antigen is the most used, despite its known issues 
regarding sensitivity and specificity 34.
Immune responses in head and neck SCC patients are 
reportedly unbalanced towards the secretion of Th2 cy-
tokines, which would prevent effective antitumour Th1 im-
mune responses 35. In the present study, we observed the 
upregulation of both Th1 (IFN-γ, IL-2 and IP-10) and Th2 
(IL-4, IL-6 and IL-10) cytokines in HNSCC patients com-
pared to healthy subjects, and the above-cited imbalance 
become evident only with regional progression, which is, 
however, the main clinical factor that affects survival in 
these patients. In fact, IFN-γ, which is among the most 
important Th1 pathway cytokines, was clearly downreg-
ulated in cases with nodal involvement and such down-
regulation displayed a linear correlation with regional 
progression. IFN-γ was also the only serum cytokine that 
displayed a protective effect when evaluated relative to 
prognosis; its crucial role in HNSCC has already been de-
scribed at both a molecular 36 and clinical level 22. In ad-
dition to IFN-γ, other cytokines that did not have specific 
Th1 activity were significantly downregulated in cases 
with nodal involvement and/or showed linear correlations 
with numeric N scores in our series, and none of these dif-
fered significantly between the cases and controls (except 
IFN-γ). Among these downregulated cytokines, IL-7 was 
recently found to perform a relevant antitumour activity 
by inducing the expansion of tumour-specific CD4+ T cell 
effectors more efficiently than IL-2 37. The serum eotaxin 
levels undergo significant modifications after the induc-
Fig. 2. When compared with controls, IL-6 serum levels were significantly higher in laryngeal but not in oral SCC patients; IP-10 levels were significantly 
higher only in oral SCC patients.
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Fig. 3. Cytokine levels that correlated significantly with the numeric N score (on the left) and/or the nodal status (on the right). Statistical significance is in-
dicated by asterisks. 
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tion of chemotherapy in head-and-neck cancer patients 38. 
Basic fibroblast growth factor expression was associated 
with good outcomes in patients with squamous cell carci-
noma of the oesophagus 39.
These data might suggest that HNSCC development in-
duces a non-specific immune response, along with in-
creased serum levels of many cytokines, but tumour cells 
tend to overcome such responses by selectively down-
regulating specific interleukins, thus promoting tumour 
progression, particularly lymphatic spreading. This phe-
nomenon would be part of tumour-mediated immunosup-
pressive activity that, according to several authors, is as-
sociated with immune escape, rapid growth and frequent 
metastasis also observed in other cancers 8 11 15. 
Conclusions
Regardless of the molecular/immunological basis of the 
findings of the present study, from a clinical point of view, 
the specific alterations associated with regional metastasis 
are very interesting for several reasons. The most immedi-
ate perspective is that downregulation of the above-cited 
cytokines, and IFN-γ in particular, could be used as risk 
markers of neck metastasis and could serve to modify the 
therapeutic recommendations by indicating, for example, 
elective neck treatment in cN0 cases and comprehensive 
neck dissection followed by adjuvant radiochemotherapy 
in pN+ cases. The prognostic role of IFN-γ could also fa-
cilitate prognostic assessments. Notwithstanding, further 
studies are necessary to confirm these findings on larger 
series and to determine the optimal cut-off value of serum 
IFN-γ for risk prediction in clinical practice.
Moreover, the suppression of IFN-γ and other cytokines, 
which we hypothesised to be tumour-dependent and to 
promote nodal metastasis, could be hindered pharmaco-
logically in attempted immunotherapy for HNSCC, as 
previously proposed for other malignancies 40.
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